Research graph
References from Association between CYP2D6 and CYP2C19 genotypes and venlafaxine treatment failure: a retrospective study on two cohorts from Norway and the UK. Local targets link to admitted publications; unresolved targets remain external evidence.
Venlafaxine therapy and CYP2D6 genotype
2012 · External reference
Venlafaxine or a second SSRI: switching after treatment failure with an SSRI among depressed inpatients: a retrospective analysis
10.1016/j.pnpbp.2011.06.007 · 2011 · External reference
Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression
10.1016/s0006-3223(02)01425-7 · 2002 · External reference
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial
10.1001/jama.299.8.901 · 2008 · External reference
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression
10.1056/nejmoa052963 · 2006 · External reference
Venlafaxine's therapeutic reference range in the treatment of depression revised: a systematic review and meta-analysis
10.1007/s00213-023-06484-7 · 2024 · External reference
O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants
10.1016/s0893-133x(98)00113-4 · 1999 · External reference
The influence of combined CYP2D6 and CYP2C19 genotypes on venlafaxine and O-desmethylvenlafaxine concentrations in a large patient cohort
10.1097/jcp.0000000000001174 · 2020 · External reference
PharmVar GeneFocus: CYP2C19
10.1002/cpt.1973 · 2021 · External reference
PharmVar GeneFocus: CYP2D6
10.1002/cpt.1643 · 2020 · External reference
Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure
10.1001/jamapsychiatry.2020.3643 · 2021 · External reference
The impact of the CYP2D6 and CYP2C19 genotypes on venlafaxine pharmacokinetics in a Japanese population
10.1007/s002280050737 · 2000 · External reference
Effects of pharmacokinetic gene variation on therapeutic drug levels and antidepressant treatment response
10.1055/a-1872-0613 · 2022 · External reference
Relation between CYP2D6 genotype, phenotype and therapeutic drug concentrations among nortriptyline and venlafaxine users in old age psychiatry
10.1055/s-0042-105443 · 2016 · External reference
Influence of the CYP2D6 isoenzyme in patients treated with venlafaxine for major depressive disorder: clinical and economic consequences
10.1371/journal.pone.0090453 · 2014 · External reference
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
10.1016/s0140-6736(07)61602-x · 2007 · External reference
The UK Biobank resource with deep phenotyping and genomic data
10.1038/s41586-018-0579-z · 2018 · External reference
Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants
10.1002/cpt.2903 · 2023 · External reference
Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2087 patients
10.1176/appi.ajp.2017.17050550 · 2018 · External reference
Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study
10.1016/s2215-0366(19)30088-4 · 2019 · External reference
Drug response pharmacogenetics for 200 000 UK Biobank participants
2021 · External reference
Distribution of venlafaxine, O-desmethylvenlafaxine, and O-desmethylvenlafaxine to venlafaxine ratio in postmortem human brain tissue
10.1111/1556-4029.12393 · 2014 · External reference
Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine
10.1002/ddr.430230210 · 1991 · External reference
Palpitations and asthenia associated with venlafaxine in a CYP2D6 poor metabolizer and CYP2C19 intermediate metabolizer
2017 · External reference
Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases
10.1038/tpj.2014.50 · 2015 · External reference
Cardiotoxicity associated with venlafaxine-defining features in a series of five cases and a call for proactive monitoring
10.3390/jcm14082792 · 2025 · External reference
Pharmacogenetic implementation studies—lessons learned from the PREPARE study
10.1002/cpt.3749 · 2025 · External reference
Metabolic activity of CYP2C19 and CYP2D6 on antidepressant response from 13 clinical studies using genotype imputation: a meta-analysis
10.1038/s41398-024-02981-1 · 2024 · External reference
